BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Oct 7, 2026; 32(37): 119668
Published online Oct 7, 2026. doi: 10.3748/wjg.119668
Table 1 Baseline characteristics of the participants (intention-to-treat set), n (%)
Characteristic
7-day PC-BMT (n = 119)
14-day PC-BMT (n = 118)
14-day P-BMT (n = 117)
P value
Sex (male)68 (57.1)61 (51.7)57 (48.7)0.421
Age (years), median (IQR)58.0 (13.0)61.0 (16.0)60.0 (13.0)0.271
Body mass index (kg/m2), median (IQR)24.5 (4.5)23.5 (3.6)23.6 (4.8)0.387
Alcohol50 (42.0)40 (33.9)54 (46.2)0.150
Smoking16 (13.5)24 (20.3)19 (16.2)0.359
Endoscopic findings
Chronic atrophic gastritis93 (78.2)88 (74.6)90 (76.9)0.805
H. pylori-induced gastritis17 (14.3)21 (17.8)14 (12.0)0.446
Gastric ulcer0.780
A1-H27 (5.9)7 (5.9)4 (3.4)
S1-S29 (7.6)6 (5.1)9 (7.7)
Duodenal ulcer0.509
A1-H22 (1.7)4 (3.4)2 (1.7)
S1-S26 (5.2)8 (7.0)12 (10.4)
Endoscopic resection of early gastric cancer or gastric adenoma4 (3.4)7 (5.9)8 (6.8)0.469
Mucosa-associated lymphoid
tissue lymphoma
0 (0.0)0 (0.0)2 (1.7)0.109
Antibiotic resistance of H. pylori
Cultured66 (55.5)67 (56.8)62 (53.0)0.839
Single resistance20 (30.3)33 (49.3)26 (41.9)0.081
Clarithromycin resistance10 (15.2)14 (20.9)8 (12.9)0.446
Amoxicillin resistance1 (1.5)3 (4.5)2 (3.2)0.694
Metronidazole resistance9 (13.6)15 (22.4)16 (25.8)0.210
Tetracycline resistance0 (0.0)1 (1.5)0 (0.0)> 0.999
Dual resistance8 (12.1)6 (9.0)7 (11.3)0.830
Clarithromycin and amoxicillin8 (12.1)4 (6.0)6 (9.7)0.467
Clarithromycin and metronidazole0 (0.0)2 (3.0)1 (1.6)0.537
Multiple resistance0 (0.0)1 (1.5)0 (0.0)> 0.999
Compliance (%), median (IQR)100.0 (0.0)100.0 (0.0)100.0 (0.0)0.671
Poor compliance (< 80%) 3 (2.5)7 (5.9)6 (5.1)0.417


Write to the Help Desk